GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (NAS:CMPS) » Definitions » Cash-to-Debt

CMPS (Compass Pathways) Cash-to-Debt : 5.13 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Compass Pathways's cash to debt ratio for the quarter that ended in Dec. 2024 was 5.13.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Compass Pathways could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Compass Pathways's Cash-to-Debt or its related term are showing as below:

CMPS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.18   Med: 74.28   Max: No Debt
Current: 5.13

During the past 7 years, Compass Pathways's highest Cash to Debt Ratio was No Debt. The lowest was 1.18. And the median was 74.28.

CMPS's Cash-to-Debt is ranked better than
75.45% of 664 companies
in the Healthcare Providers & Services industry
Industry Median: 0.77 vs CMPS: 5.13

Compass Pathways Cash-to-Debt Historical Data

The historical data trend for Compass Pathways's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Compass Pathways Cash-to-Debt Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial No Debt 75.61 74.28 6.66 5.13

Compass Pathways Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.66 8.01 7.01 6.36 5.13

Competitive Comparison of Compass Pathways's Cash-to-Debt

For the Medical Care Facilities subindustry, Compass Pathways's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Compass Pathways's Cash-to-Debt falls into.


;
;

Compass Pathways Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Compass Pathways's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Compass Pathways's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Compass Pathways  (NAS:CMPS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Compass Pathways Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Compass Pathways's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Executives
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Ekaterina Malievskaia officer: Chief Innovation Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
George Jay Goldsmith director, 10 percent owner, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 1 ASHLEY ROAD, 3RD FLOOR, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mary-rose Hughes officer: Interim CFO C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F0DQ
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Kabir Nath director, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F 0DQ
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
David Y Norton director 8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Matthew A Owens officer: General Counsel & CLO 1900 POLARIS PARKWAY, COLUMBUS OH 43240
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Linda Mcgoldrick director C/O AVADIM HEALTH, INC., 81 THOMPSON STREET, ASHEVILLE NC 28803
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Robert Mcquade director C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Michael Falvey officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Guy Goodwin officer: Chief Medical Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT